Moberg Pharma publishes information document on the proposed divestment of the OTC-business

STOCKHOLM, February 4th, 2019. On February 12th, 2019, it was announced that Moberg Pharma AB (publ) (“Moberg Pharma” or the “Company”) has entered into agreement with RoundTable Healthcare Partners and Signet Healthcare Partners to divest its entire commercial operations. Further information regarding the proposed divestment of the OTC-business has today been published and is available in the form of an information document.

The information document describes the proposed transaction as well as the Company’s continued operations following a divestment of the OTC-business. The information document contains among other things financial pro forma information in the form of income statement and balance sheet for 2018, the background and reasons for the proposed divestment and detailed information regarding the different elements of the transaction.

The information document is only available in Swedish. However, the pro forma information is available in English in the form of a translation. The information document and the translation are available on the Company’s website,

The published information document is to be used for information purposes only and as a basis for assessing the consequences of the proposed divestment of the OTC-business of Moberg Pharma and actions related thereto, which are described in the information document. The information document does not contain or constitute an invitation or an offer to acquire, sell, subscribe for or otherwise trade in shares or other securities in Moberg Pharma. The published information document has not been approved by any regulatory authority and is not a prospectus.

For additional information, please contact: 
Peter Wolpert, CEO, phone: Sweden: +46 707 35 7135, US: +1 908 432 2203, e-mail:
Anna Ljung, CFO, phone: +46 707 66 6030, e-mail:

About this information              
The information was submitted for publication, through the contact persons set out above, at 8.30 a.m. (CET) on March 4th, 2019.


About Us

Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The company’s main asset, MOB-015, is a novel topical treatment for onychomycosis, with recently completed phase 3 trials in more than 800 patients. The pipeline also includes the late-stage asset BUPI for pain relief in oral mucositis. Clinical data generated for both assets indicate they have the potential to become market leaders in their respective niches. Moberg Pharma is headquartered in Stockholm and the company’s shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB).